Finnegan's Take

Archives for Science & Research

Amid resignations, political spats and question marks over its budget, there’s a new broom at the EU’s powerful medicines authority Pity Guido Rasi. Not for his €200 salary, the generous perks or the swanky Canary Wharf offices, but for the unenviable task of turning around the ailing European Medicines Agency. He takes the helm at… » read more

Posted by Gary Finnegan

The draft EU budget is a win for Geoghegan-Quinn but it won’t make her popular at home. The EU’s budget has been the subject of much wrangling of late, with the usual tug-of-war between interest groups from industry, agriculture and the rest. Ireland’s European Commissioner Máire Geoghegan-Quinn, who is responsible for research, innovation and science,… » read more

Posted by Gary Finnegan

The EU’s clinical trials directive has been a catastrophe but Brussels is keen to make amends “Arguably the most criticised piece of legislation” the EU has ever produced on medicines. That’s how the European Commission describes its own law on clinical trials, drafted a decade ago in an effort to streamline medical research in Europe.… » read more

Posted by Gary Finnegan

“European Research Council in full flight,” screams the July issue of the Europe4Researchers newsletter published by the European Commission, which landed in my inbox on this afternoon. The article boasts that the ERC has “developed into a well-functioning research funding body”. Great news, if it were true. Yesterday a panel of experts – assembled by… » read more

Posted by Gary Finnegan

Oh dear. As if the debate on nanotechnology were not complex enough, it now seems companies are quietly burying references to nanomaterials contained in consumer produts. Until recently, branding something as containing ‘nanotechnology’ was seen as a plus – a marketing boost. Now though, a new pattern is emerging. Consumer groups in Norway, the UK… » read more

Posted by Gary Finnegan